Chen Lin's Perfect Biotech Market Prescription: Buy Low, Sell High!
Source: Peter Byrne of The Life Sciences Report  (2/20/14)
Charming and smart, Chen Lin makes a lot of money by jumping in and out of the highly volatile biotech market while obeying a set of simple rules, which he reveals in this interview with The Life Sciences Report. Applying his strong science background, Lin zeros in on biotech firms with solid products. The trick is in having the guts to buy low and sell high, against the market tide, says the editor of the widely respected newsletter, What is Chen Buying? What is Chen Selling? Lin also brings us up to date on his favorite picks. More >

Catalysts Drive These Stocks: Mara Goldstein
Source: George S. Mack of The Life Sciences Report  (2/20/14)
Whether biotech stocks keep up the scorching pace of 2013 remains to be seen, but we can count on one thing going forward, says Cantor Fitzgerald Senior Analyst Mara Goldstein. We are still in a catalyst-driven market. In this interview with The Life Sciences Report, Goldstein discusses four names with approaching milestones that she believes are important growth drivers. Her fifth pick is a binary event story, meaning it could skyrocket on good data or plummet on bad. More >

Big Pharma Continues the Race for Electroporation
Source: Brian Nichols, Wall St. Cheat Sheet  (2/17/14)
"Electroporation is a delivery platform that uses an electrical pulse to create temporary pores in cells." More >

Big Pharma Will Find Good Hunting Among Early-Stage Biotechs: Dhesh Govender
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (2/13/14)
Dhesh Govender, manager of the life sciences portfolio for Cedar Lane Enterprises Inc., has the inside track when it comes to identifying the hottest biotech trends. In this interview with The Life Sciences Report, Govender explains why he thinks plenty of upside remains in the life sciences sector, and reveals trade secrets that every investor should consider when building a successful investment strategy. More >

Regenerative Medicine Finally Gets Some Respect: Reni Benjamin
Source: JT Long of The Life Sciences Report  (2/11/14)
Of the many themes that propelled the biotech sector to record returns in 2013, regenerative medicine and therapeutics targeting cancer were front and center. In this interview with The Life Sciences Report, Reni Benjamin, managing director and equity research analyst at H.C. Wainwright & Co., talks about two companies with impending catalysts that play on these themes, and offers his take on the prospects for the regenerative medicine sector going forward. More >

The Best Biotech Takeover Targets for 2014
Source: Kyle Anderson, Money Morning  (2/10/14)
"Large-cap pharmaceutical companies, instead of starting from scratch on a new patent, want an easier and more effective way to replace their lost "cash-cow" revenue. They will look to acquire biotech companies—and their phase 2 or phase 3 drugs." More >

Do Away with the Pill-A-Day Biotech Model: Steve Brozak
Source: George S. Mack of The Life Sciences Report  (2/6/14)
The U.S. healthcare system is untenable, says Steve Brozak, president of WBB Securities. The solution-oriented Brozak is on the hunt for biotech and medical device companies that fit a new paradigm, in which budgets are restrained and companies generate curative therapies for unmet needs. In this interview with The Life Sciences Report, Brozak takes aim at a broken system and lists ten problem-solving companies that can adapt to the changes he believes must take place for healthcare to be profitable and productive. A bonus: These companies can also add vigor to investment portfolios. More >

Ram Selvaraju: A Pair of Companies Ride the Sea Change in Cancer Therapeutics
Source: George S. Mack of The Life Sciences Report  (2/4/14)
A new generation of oncology treatments is moving through clinical trials toward the market. These proposed products are revolutionary in both their approaches to disease and their expected efficacy. Raghuram "Ram" Selvaraju, armed with his background as a drug developer, has followed dozens of highly innovative small- and mid-cap biotech companies, many of which he originally spotted as micro caps. In his second of three interviews with The Life Sciences Report, the head of equity healthcare research at Aegis Capital Corp. highlights two names with huge growth prospects. More >

Two Companies Follow Unmet Needs to Biotech Profits: Echo He
Source: George S. Mack of The Life Sciences Report  (1/30/14)
Disease progression and drug resistance mean that very sick patients ultimately run out of options. In the case of orphan diseases, patients often run out of alternatives immediately after they are diagnosed. In this interview with The Life Sciences Report, Echo He of the Maxim Group discusses her focus on how patients with unmet needs might ultimately get a fighting chance. To that end, she has selected two names that could produce both welcome cures and stunning share price results for investors who understand the value proposition of last-resort therapies. More >

The Year of RNA?
Source: Karl Thiel, BioSpace.com   (1/28/14)
So 2013 was a huge year for RNA, but could 2014 be even bigger? More >

The Last Word: Place Your Biotech Bets on Solid Management and Hot Therapy Areas
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (1/23/14)
Who got the last word at the 2014 Biotech Showcase? A portfolio manager specializing in healthcare, an award-winning analyst, and a pair of venture capitalists with global viewpoints and a focus on clinical-stage companies. In the closing event of the showcase, cohosted by The Life Sciences Report, this panel of experts offered insights into trends that will influence the biotech universe in 2014. More >

Biotech Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (1/15/14)
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist, which was released at the Biotech Showcase in San Francisco, reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices. Credit the basket of stocks picked by industry experts, weighted heavily with winners. Can our panel of experts pick another winning portfolio in 2014? Find out which companies they've chosen for the 2014 Watchlist in this exclusive from The Life Sciences Report
and Sagient Research. More >

Biotech Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (1/15/14)
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices. Credit the basket of stocks picked by industry experts, weighted heavily with winners. Can our panel of experts pick another winning portfolio in 2014? Find out which companies they've chosen for the 2014 Watchlist in this exclusive from The Life Sciences Report.
More >

Biotech Showcase Watchlist 2014: Sound Science, Innovative Ideas and a Sprinkle of Pixie Dust
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (1/15/14)
2013 was a banner year for the life sciences sector, with biotech, pharmaceutical and medtech companies buoyed by advances in therapeutic techniques, a friendly regulatory environment, lucrative partnerships and the overall market upswing. The 2013 Biotech Watchlist, which was released at the Biotech Showcase in San Francisco, reflected this robustness, boasting a year-to-date return that blew past those posted by the major indices. Credit the basket of stocks picked by industry experts, weighted heavily with winners. Can our panel of experts pick another winning portfolio in 2014? Find out which companies they've chosen for the 2014 Watchlist in this exclusive from The Life Sciences Report and Sagient Research.
More >

Sorting Through the Chaff: The Michael J. Fox Foundation's Tracey Mumford on the Quest to Cure Parkinson's Disease
Source: George S. Mack of The Life Sciences Report  (1/9/14)
The business of drug development survives by saving lives, but sometimes nonprofit, private activism is needed to kick-start a new medicine into development. The Michael J. Fox Foundation for Parkinson's Research is the world's largest nonprofit funder of Parkinson's disease research, having awarded more than $400 million in grants during its 13-year existence. Senior Associate Director of Research Partnerships Tracey Mumford is the foundation's link to companies with good ideas. In this interview with The Life Sciences Report, Mumford discusses exciting companies that have warranted foundation support—companies that investors might find very interesting. More >

The Biological iPhone
Source: Ray Blanco, The Daily Reckoning  (1/3/14)
"The next Steve Jobs might be tinkering with DNA molecules instead of circuit boards." More >

Follow the M&A Money to Small- and Mid-Cap Cardiovascular Medtechs: Jason Mills
Source: George S. Mack of The Life Sciences Report   (1/2/14)
Some investors' eyes glaze over at the mention of medical devices. But it's time to wake up and focus on the stunning growth opportunities in small- and mid-cap cardiovascular medtech. Canaccord Genuity Managing Director Jason Mills covers companies on the front lines of innovation and in sectors where the trifecta of revenue, margins and reimbursement is achieving biotechlike levels. In this interview with The Life Sciences Report, Mills opens the new year with a discussion of the cardiovascular medtech industry and mentions companies that are probable acquisition candidates. More >

5 Companies with Upcoming Catalysts that Should Rally into 2014
Source: Scott Matusow, BioMed Reports  (12/31/13)
"In the developmental biopharma segment of the market that we follow daily at stockmatusow, stock prices sometimes experience volatile moves, especially as a near-term catalyst event approaches." More >

Coming of Age: Experts Reflect on the Extraordinary Promise of the Cell Therapy Sector
Source: Tracy Salcedo-Chourré of The Life Sciences Report  (12/26/13)
Without innovation and risk-taking, modern medicine would be missing staples of the physician's armamentarium: antibiotics, radiation therapies, vaccines. The idea of taking a tonic to cure what ails you is thousands of years old, but the science behind that tonic may be revolutionary. Enter stem cell technologies. Given the promise backing the science—and the sector's position on the cusp of breaking out—companies with cell therapies got plenty of attention from investment analysts and experts in 2013. Read what those experts, including George Zavoico of MLV & Co., Steve Brozak of WBB Securities, Jason Kolbert of the Maxim Group, and Kevin DeGeeter of Ladenberg Thalmann & Co., had to say about prospects for stem cell companies in this special retrospective article from The Life Sciences Report. More >

Micro-Cap Medtech with Explosive Upside Potential: Brian Marckx
Source: George S. Mack of The Life Sciences Report   (12/19/13)
Combine the complexity of genomic testing with the high risk inherent in micro-cap stocks, and you have investment opportunities that require exceptional diligence. The reward for understanding the value proposition of budding companies? The payoff can be enormous. In this interview with The Life Sciences Report, Senior Medical Device Analyst Brian Marckx of Zacks Investment Research has selected eight micro-cap names that could return triples, quads and more for investors willing to do their homework. More >

The New Year Heralds a Transition in Stem Cell Development: Jason Kolbert
Source: George S. Mack of The Life Sciences Report   (12/17/13)
The cell therapy industry has been mired in phase 1 and 2 studies for what seems like a lifetime. But 2014 is shaping up to be a banner year for share-moving phase 2 data and pivotal phase 3 activity. Jason Kolbert, managing director for biotechnology research at Maxim Group, leverages his deep understanding of the stem cell space to uncover viable therapies that double as excellent business models. In this interview with The Life Sciences Report, Kolbert guides investors to regenerative medicine companies that have evolved beyond great science projects into businesses capable of generating huge margins and disrupting the paradigm of medical practice. More >

3-D Printing: Will Drug Production Become a DIY Project?
Source: J.D. Tuccille, The Daily Reckoning  (12/13/13)
"Both research and production look poised for a revolution as 3-D printing applies its high-tech charms to the business of creating chemical compounds and turns the production of medicine into a DIY project." More >

Shopping for Biotech Growth Names: Reni Benjamin
Source: George S. Mack of The Life Sciences Report  (12/12/13)
Get ready for a bonanza of biotech names. Managing Director and Equity Research Analyst Reni "Ren" Benjamin is a new arrival at H.C. Wainwright & Co., and he's busy doing diligence on a lot of stocks. Along with three Buy-rated biotechs he's already initiated coverage on, Benjamin brought The Life Sciences Report a bonus package of names that could fatten investors' portfolios. Backed by Benjamin's extensive industry knowledge, this long shopping list includes companies poised to make drug development history. More >

How to Pick Biotech Stocks
Source: David Petch, Wealth Daily  (12/9/13)
"Intellectual property is one of the most important and valuable assets a company has. IP essentially gives someone a monopoly for producing a product against certain indications for up to 20 years. Finding companies with great ideas that follow through with investing in patent protection creates a potential short list of investments, as a successful product could have exclusivity in the marketplace." More >

Not Your Father's Diagnostics: Ram Selvaraju on How Molecular Genomics Invigorate the Sector
Source: George S. Mack of The Life Sciences Report.  (12/5/13)
An old investment principle says the equity upside of diagnostics and tools companies can't hold a candle to that of small biotech drug developers. Raghuram "Ram" Selvaraju, managing director and head of equity healthcare research at Aegis Capital, begs to differ. His research has uncovered small- and micro-cap companies developing sophisticated platforms in the molecular diagnostics space that are destined for significant revenue growth and profits. In his first of three interviews with The Life Sciences Report, Selvaraju lays out a handful of names with powerful technologies on the cusp of investor acceptance as huge growth plays. More >